##  [Novartis at ESMO](/news/novartis-esmo "Novartis at ESMO") 

 Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)



 

 Sep 17, 2020 

## Novartis 2020 ESMO Annual Meeting Virtual Portal

 ![Novartis at ESMO](/sites/novartis_com/files/styles/crop_freeform/public/2021-07/esmo-congress-image.jpg.webp?itok=7_xoXUBE "Novartis at ESMO")

 

We are boldly reimagining cancer and blood disorders.

[Enter Portal](https://www.virtualcongress.novartis.com/esmo20/?utm_medium=referral&utm_source=novartis.com&utm_campaign=corporate_website_post_oncology)

---

.tb_button {padding:1px;cursor:pointer;border-right: 1px solid #8b8b8b;border-left: 1px solid #FFF;border-bottom: 1px solid #fff;}.tb_button.hover {borer:2px outset #def; background-color: #f8f8f8 !important;}.ws_toolbar {z-index:100000} .ws_toolbar .ws_tb_btn {cursor:pointer;border:1px solid #555;padding:3px}   .tb_highlight{background-color:yellow} .tb_hide {visibility:hidden} .ws_toolbar img {padding:2px;margin:0px}
.tb_button {padding:1px;cursor:pointer;border-right: 1px solid #8b8b8b;border-left: 1px solid #FFF;border-bottom: 1px solid #fff;}.tb_button.hover {borer:2px outset #def; background-color: #f8f8f8 !important;}.ws_toolbar {z-index:100000} .ws_toolbar .ws_tb_btn {cursor:pointer;border:1px solid #555;padding:3px}   .tb_highlight{background-color:yellow} .tb_hide {visibility:hidden} .ws_toolbar img {padding:2px;margin:0px}

.tb_button {padding:1px;cursor:pointer;border-right: 1px solid #8b8b8b;border-left: 1px solid #FFF;border-bottom: 1px solid #fff;}.tb_button.hover {borer:2px outset #def; background-color: #f8f8f8 !important;}.ws_toolbar {z-index:100000} .ws_toolbar .ws_tb_btn {cursor:pointer;border:1px solid #555;padding:3px}   .tb_highlight{background-color:yellow} .tb_hide {visibility:hidden} .ws_toolbar img {padding:2px;margin:0px}


 



## Press releases

- [Novartis announces new survival data for its treatment for advanced breast cancer with a specific mutation will be presented at the ESMO Virtual Congress 2020](/news/media-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-metastatic-breast-cancer "Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer")
- [Novartis reports late-breaking data from Phase III study in advanced melanoma](/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma "Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma ")
- [Novartis announces its advanced breast cancer treatment receives highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale](/news/media-releases/novartis-kisqali-receives-highest-rating-any-cdk46-inhibitor-esmo-magnitude-clinical-benefit-scale "Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale")